丹参酮联合克拉霉素治疗鼻咽癌放疗后鼻-鼻窦及咽部损伤

Clarithromycin combined with tanshinone for rhinosinusal and laryngeal radiation injury in patients with nasopharyngeal carcinoma after radiotherapy

目的观察丹参酮与克拉霉素联合用药对鼻咽癌放疗后鼻-鼻窦及咽部损伤的治疗效果,以探索鼻咽癌放疗后鼻-鼻窦及咽部损伤的最佳治疗方案。方法将255例中放疗后出现鼻-鼻窦及咽部损伤的鼻咽癌患者,按发生时间顺序随机分为克拉霉素组(A组)丹参酮组(B组)以及克拉霉素+丹参酮联合用药组(C组),观察各组的治疗预后情况。结果 A、B、C 3组均有治疗效果,与治疗前比较差异具有统计学意义(P<0.05);A组与B组之间疗效差异不明显(P>0.05);而C组的疗效明显好于A组和B组(P<0.05)。结论多元化治疗是鼻咽癌放疗后鼻窦及咽部损伤治疗的趋势,克拉霉素+丹参酮联合用药是治疗鼻咽癌放疗后鼻窦及咽部损伤非常有效的手段和方法。

Objective To evaluate the therapeutic effect of clarithromycin combined with tanshinone in the treatment of rhinosinusal and laryngeal radiation injury induced by radiotherapy in patients with nasopharyngeal carcinoma （NPC）. Methods A total of 255 NPC patients with rhinosinusal and laryngeal radiation injury following radiotherapy were randomized into 3 groups for treatment with clarithromycin （group A, n=69）, tanshinone （group B, n=69）, and clarithromycin ＋ tanshinone （group C, n=69）, and the clinical outcomes of the patients were evaluated. Results In all the 3 groups the patients responded favorably to the treatments and showed obvious improvements （P〈0.05）. The therapeutic effects were similar between groups A and B （P〉0.05）, but the patients in group C showed the most obvious improvements （P〈0.05）. Conclutions Clarithromycin combined with tanshinone can be an effective regimen for treatment of rhinosinusal and laryngeal radiation injury induced by radiotherapy in NPC patients.